On a November morning, a small South Korean biotech named Medpacto stepped into one of medicine's hardest rooms, announcing that its experimental drug MP010 had erased pancreatic tumors entirely in most of the mice it was tested on. The findings, carried as the cover paper of a respected oncology journal, speak to an old human hope: that the ground a tumor grows in can be changed as well as the tumor itself. Yet the story is still a story told in animals, and the larger chapter, whether these results will hold in people, has not yet been written.
Medpacto Reports Preclinical Pancreatic Cancer Data for MP010, Citing Immune Memory Mechanism
Changing the soil, regardless of the seed
Mark
Eighty-seven and a half percent complete response sounds enormous. Why is this getting attention?
Mimi
Pancreatic cancer is among the hardest to treat, and these were three models chosen because they respond poorly to treatment. Complete tumor clearance in that setting is unusual.
Luke
Worth saying plainly, though: these are animal models, and the company is the source of the figures. The 87.5% is the top of a 75.0–87.5% range, and the report doesn't give group sizes.
Mark
The re-implantation result seems to be the real headline. Why?
Mimi
Because it suggests more than killing a tumor. Animals that had cleared the cancer didn't grow tumors when the same cells were injected again, and most resisted other cancer types too.
Luke
The T-cell memory explanation is the researchers' own analysis. The data show tumors didn't form; the mechanism is their interpretation, albeit published in Cancer Cell.
Mark
What's different about targeting TGF-β this way?
Mimi
Earlier TGF-β inhibitors hit the whole body and caused toxicity in normal tissue. MP010 binds EDB-FN, which is concentrated around tumors, so the action is meant to stay local.
Luke
Meant to. That selectivity is a design intention. Toxicity data is still being organized for the IND filing, so safety in humans is unknown.
Mark
So what should a reader watch next?
Mimi
IND approval, targeted for early next year, then trials in South Korea and the United States, plus whether the licensing talks turn into a deal.
Luke
And remember the quotes about game changers and broad-spectrum agents are executives' expectations, not findings.
El Pulso
- Pancreatic cancer, which resists most treatments, now shows a flicker of possibility in animal models where tumors disappeared in up to 87.5% of cases.
- The most startling claim is that treated animals resisted the same cancer returning, suggesting the immune system learned to remember the disease.
- MP010 targets the tumor's surrounding barrier and TGF-β, aiming to spare healthy tissue where older drugs of this class caused harm.
- Medpacto is racing toward human trials in South Korea and the United States, aiming for IND approval early next year while courting global licensing partners.
- The field remains cautious: the results exist only in animals, and investors are waiting to see whether the timing and deals materialize.
On a November morning, a small South Korean biotech named Medpacto stepped into one of medicine's hardest rooms, announcing that its experimental drug MP010 had erased pancreatic tumors entirely in most of the mice it was tested on. The findings, carried as the cover paper of a respected oncology journal, speak to an old human hope: that the ground a tumor grows in can be changed as well as the tumor itself. Yet the story is still a story told in animals, and the larger chapter, whether these results will hold in people, has not yet been written.
On the 10th, the South Korean biotech Medpacto announced that its experimental drug MP010 had cleared tumors completely in up to 87.5% of animals in three preclinical models of pancreatic cancer, a disease that rarely yields to treatment. The findings appeared as the cover paper of the November issue of Cancer Cell.
The result that drew the most attention was about recurrence. When the same cancer cells were injected again into animals whose tumors had vanished, no new tumors formed. Even when different cancer types were implanted, more than 80% of cases failed to take hold. The researchers credit CD4+ and CD8+ T cells, which appear to have kept a lasting memory of the cancer. The company says this is the first study to show an anticancer effect working through immune memory.
MP010 works on two fronts. It binds to a protein overexpressed around tumors and blocks TGF-β, the factor cancers use to disable immune defenses. Older TGF-β inhibitors acted throughout the body and caused serious side effects. MP010 is designed to act only in the tumor's immediate surroundings. Kim Sung-jin, the chairman who led the work, described it as changing the soil rather than only the seed, arguing that this can work even when cancer cells are genetically varied.
At the same time, the company is pushing toward the clinic. It plans to compile toxicity data and begin trials in South Korea and the United States, aiming for IND approval early next year, and it is in talks with several global drugmakers about joint research and licensing. Those conversations are still open.
The announcement follows a series of setbacks for TGF-β drugs. If MP010's targeted design holds in people, it could offer something new for solid tumors with few options. But the animal results have not yet shown what they would mean for human patients, and that question remains open.
On the 10th, the South Korean biotech Medpacto announced that its experimental cancer drug MP010 had cleared tumors completely in up to 87.5% of animals in preclinical models of malignant pancreatic cancer. The work was published as the cover paper of the November issue of Cancer Cell, a leading journal in the field.
The figures come from three animal models of pancreatic cancer, all of them types that respond poorly to treatment. Across those models, the complete response rate ran from 75.0% to 87.5%, and the long-term survival rate was 87.5%. These are animal results, and the company is clear that human data does not yet exist.
The more striking finding concerns recurrence. When the researchers injected the same cancer cells again into animals whose tumors had fully disappeared, no tumors formed in any of them. When they implanted different cancer types instead, including other pancreatic cancer cells as well as lung and bladder cancer cells, tumors failed to form in more than 80% of cases. The researchers attribute this to CD4+ and CD8+ T cells acquiring a long-lasting immune memory of the cancer. Medpacto says this is the first study anywhere to show an anticancer effect working through immune memory.
MP010 is a dual-mechanism drug. It binds selectively to extra domain-B fibronectin (EDB-FN), a protein overexpressed in the tumor microenvironment, and at the same time targets TGF-β, the factor that helps cancers evade the immune system and spread. Conventional TGF-β inhibitors act throughout the body and cause significant side effects in normal tissue. MP010 is designed to act only in the area around the tumor. The company says it breaks down the defensive barrier surrounding cancer cells while prompting the attacking immune cells to remember the cancer.
Kim Sung-jin, Medpacto's chairman, who led the research, described the logic in terms of seed and soil. Cancer cells secrete TGF-β to disable the immune system and reshape their surroundings in the tumor's favor, he said, and the study showed that blocking TGF-β around the cancer produced complete cures and long-term immune effects. Even when the seed, the cancer cell, is genetically diverse, he argued, changing the soil can allow treatment and prevention of recurrence. CEO Woo Jung-won said the work shows TGF-β inhibitors could expand into broad-spectrum anticancer agents, and he called MP010 a potential game changer. Kang Dong-woo, head of Research Division 1, was first author of the paper.
The company is moving on commercialization at the same time. It plans to compile MP010's toxicity data and enter clinical trials in South Korea and the United States, aiming for Investigational New Drug (IND) approval early next year. It is in talks with several global pharmaceutical companies about joint research and licensing, and held about 20 meetings at Bio Japan 2026 last month, based on its preclinical data and clinical plans. MP010 was selected last year for support from the Korea Drug Development Fund and is receiving government research funding. Separately, Medpacto's lead pipeline drug Bactoserpin, in a Phase 2 trial for osteosarcoma, received approval from South Korea's Ministry of Food and Drug Safety in September to amend its trial plan by adding a medium-dose patient group.
The announcement lands after a run of setbacks for TGF-β-class cancer drugs, which have struggled with systemic toxicity. If MP010's tumor-selective design holds up in clinical trials, some assessments suggest it could become a new option in solid tumors with few treatments, such as pancreatic cancer. But whether animal results will translate into efficacy and safety in people remains to be shown. For now, investors in South Korean biotech are watching two things: the timing of IND approval and whether the global licensing talks produce a deal.
Citas Notables
Blocking TGF-β around the cancer produced complete cure and long-term immune effects.— Kim Sung-jin, chairman of Medpacto
The results show the potential for TGF-β inhibitors to expand into broad-spectrum anticancer agents.— Woo Jung-won, CEO of Medpacto
Quieres la nota completa?
Lee el original en BigGo Finance ↗
Health & Medicine